Friday, July 10, 2026

Intelligence · Clinical pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs 985

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 985 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Pipeline programs

Page 16 of 21
  1. An open-label for inteneded for treatment of - ac…

    Lacuna Pharma Pty Ltd

    inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.

    phase 1 other active

    1 trial
  2. Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody

    Takeda

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial
  3. Atorvastatin

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial
  4. Azercabtagene zapreleucel (azer-cel)

    TG THERAPEUTICS, INC.

    B-cell Mediated Autoimmune Disorders

    phase 1 small molecule active

    1 trial
  5. BCMA/CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial
  6. BMS-986202

    Bristol-Myers Squibb

    Psoriasis

    phase 1 small molecule completed

    1 trial
  7. C6341001

    Pfizer Australia Pty Ltd

    Rheumatoid arthritis and Systemic Lupus Erythematosus

    phase 1 other active

    1 trial
  8. CA061-1001

    Celgene Europe Limited

    Systemic Sclerosis, Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial
  9. CA061-1006

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial
  10. CAIN457E22101

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial
  11. CB-010

    Caribou Biosciences

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial
  12. CBP-307

    S.L

    Autoimmune Diseases

    phase 1 small molecule completed

    2 trials
  13. CBP-307

    Connect Biopharm

    Autoimmune Diseases

    phase 1 small molecule completed

    1 trial
  14. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial
  15. CD19 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    SLE (Systemic Lupus)

    phase 1 mab active

    1 trial
  16. CD19/BCMA in vivo CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Diseases

    phase 1 small molecule active

    1 trial
  17. CLN-978

    Cullinan Therapeutics

    Rheumatoid Arthritis (RA

    phase 1 small molecule active

    1 trial
  18. CLN-978-RA-101

    Cullinan Therapeutics

    Treatment-Refractory Rheumatoid Arthritis

    phase 1 other active

    1 trial
  19. CLN-978-SL-101

    Cullinan Therapeutics

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial
  20. CNCT19 CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Hemolytic Anemia

    phase 1 mab active

    1 trial
  21. CNCT19 cell injection

    Juventas Cell Therapy

    Neurological Autoimmune Diseases

    phase 1 mab active

    1 trial
  22. CNTY-101

    Century Therapeutics

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial
  23. CNTY-101-151-01

    Century Therapeutics

    systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]

    phase 1 other active

    1 trial
  24. CNTY-LTFU-01

    Century Therapeutics

    Hematological or solid tumor malignancies or autoimmune diseases

    phase 1 other active

    1 trial
  25. CPIT565B12101

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial
  26. CPIT565C12101

    Novartis Pharmaceuticals

    Rheumatoid Arthritis

    phase 1 other active

    1 trial
  27. CTX112

    S.A.

    SLE (Systemic Lupus)

    phase 1 mab active

    1 trial
  28. D740AC00001

    AstraZeneca AB

    Systemic Lupus Erythematosus, Rheumatoid Arthritis

    phase 1 other active

    1 trial
  29. D9640C00001

    AstraZeneca AB

    Rheumatoid Arthritis

    phase 1 other active

    1 trial
  30. D9690C00007

    AstraZeneca AB

    Crohn's disease

    phase 1 other active

    1 trial
  31. D9961C00001

    AstraZeneca AB

    Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies

    phase 1 other active

    1 trial
  32. DEUCR-07-25

    Lacuna Pharma Pty Ltd

    plaque psoriasis

    phase 1 other active

    1 trial
  33. DEUCR-08-25

    Lacuna Pharma Pty Ltd

    plaque psoriasis

    phase 1 other active

    1 trial
  34. Delayed Release 6 mercaptopurine

    Teva Pharma GmbH

    Crohns Disease

    phase 1 small molecule completed

    1 trial
  35. EP-104IAR

    EUPRAXIA PHARMACEUTICALS INC.

    Osteoarthritis, Knee

    phase 1 small molecule completed

    1 trial
  36. Effect of Renal Impairment on Enpatoran Pharmacokinetics

    Merck Sharp and Dohme

    Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).

    phase 1 other active

    1 trial
  37. Etrasimod Arginine Blue

    Pfizer Australia Pty Ltd

    Ulcerative Colitis and immune-mediated inflammatory disorders

    phase 1 small molecule active

    1 trial
  38. FT819 in B-cell Mediated Autoimmune Diseases

    Zafatek

    B-cell Mediated Autoimmune Diseases

    phase 1 other active

    1 trial
  39. FX201

    Pacira Ireland Limited

    Osteoarthritis, Knee

    phase 1 mab active

    1 trial
  40. Fasinumab AI

    Regeneron UK Limited

    Osteoarthritis, Knee

    phase 1 small molecule completed

    1 trial
  41. GA43191

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial
  42. GA46438

    Hoffmann-La Roche

    Active Ulcerative Colitis (UC)

    phase 1 other active

    1 trial
  43. GBP-NIB1-101

    Lacuna Pharma Pty Ltd

    rheumatoid arthritis

    phase 1 other active

    1 trial
  44. GLPG-0634-CL-131

    Alfasigma S.p.A.

    juvenile idiopathic arthritis

    phase 1 small molecule active

    1 trial
  45. GLPG1972 600 mg oral solution fasted

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 1 small molecule completed

    1 trial
  46. GLPG1972 cohort 1

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 1 small molecule completed

    1 trial
  47. GLPG3667

    Lakefront Biotherapeutics NV

    Plaque Psoriasis

    phase 1 small molecule completed

    1 trial
  48. GLPG3970 film-coated tablet

    Lakefront Biotherapeutics NV

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

985 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.